Medications such as semaglutide, best known under the brand name Ozempic, have transformed the treatment of obesity and metabolic disease. These GLP-1 receptor agonists are now widely used for weight loss, raising an obvious question for couples trying to conceive: do drugs like Ozempic affect male fertility?
Unlike the discussion around Ozempic and female fertility, where ovulation changes can occur relatively quickly, the relationship between GLP-1 drugs and male fertility is less direct. In most cases, the more important factor appears to be the patient’s underlying metabolic health rather than the medication itself.
To understand whether Ozempic and male fertility are connected, it is necessary to start with a well-established finding in reproductive medicine: obesity itself can impair sperm production.
Obesity and Male Fertility
A large body of research has linked obesity to poorer semen quality and lower testosterone levels.
A systematic review published in Human Reproduction Update found that obesity in men is associated with reduced sperm concentration and total sperm count. The proposed mechanisms include hormonal disruption, increased estrogen production from adipose tissue, and metabolic inflammation affecting the testes.
In practical terms, this means that metabolic health — not just reproductive anatomy — plays a significant role in male fertility.
Weight Loss Can Improve Sperm Count
Because obesity can impair sperm production, researchers have studied whether weight loss can improve sperm health.
A randomized clinical trial published in Human Reproduction examined obese men who underwent a structured weight-loss program. Researchers found that significant weight loss was associated with increases in sperm concentration and total sperm count.
Importantly, the improvement was maintained when weight loss was sustained.
This finding is particularly relevant when considering GLP-1 medications, because these drugs often produce substantial weight reduction.
GLP-1 Drugs and Male Reproductive Hormones
Direct research examining GLP-1 drugs and male fertility is still limited, but some studies have begun to explore how these medications influence reproductive hormones.
In a study of obese men treated with the GLP-1 receptor agonist liraglutide, researchers observed improvements in testosterone levels along with metabolic health markers.
Although liraglutide is not identical to semaglutide, both belong to the same class of GLP-1 receptor agonists and produce similar metabolic effects.
Researchers believe that improvements in insulin sensitivity, reduced inflammation, and weight loss may help normalize hormone signaling involved in sperm production.
What We Know So Far
Despite growing interest in Ozempic and male fertility, there are still significant gaps in the data.
Most clinical trials of semaglutide focused on diabetes and obesity outcomes. Male fertility parameters such as sperm count, motility, and DNA integrity were not primary endpoints.
As a result, scientists do not yet have large studies directly evaluating how semaglutide affects sperm production.
In addition, rapid weight loss — regardless of the method used — can temporarily alter hormone levels while the body adapts to metabolic change.
For these reasons, experts generally frame the relationship between GLP-1 drugs and male fertility cautiously: the metabolic improvements associated with weight loss may benefit reproductive health, but the direct effects of the medications themselves remain under investigation.
What Fertility Specialists Want Patients to Know
The strongest evidence linking GLP-1 medications and male fertility comes from the broader relationship between metabolic health and reproductive function.
Obesity, insulin resistance, and hormonal disruption can impair sperm production. Improving metabolic health — whether through lifestyle changes, medical therapy, or weight loss — may help restore healthier reproductive hormone signaling.
However, medications such as Ozempic should not be viewed as fertility treatments. Men who are taking semaglutide and planning to conceive may benefit from discussing their health history, medications, and reproductive goals with a fertility specialist.
A simple semen analysis can often provide the most direct insight into male reproductive health.
Why New Hope?
Research on GLP-1 medications such as semaglutide and Ozempic and male fertility is still emerging. Some studies suggest that weight loss and improved metabolic health may support better hormone balance and sperm production, but more data is needed.
Men planning to conceive may benefit from a semen analysis and a discussion with a fertility specialist. For evaluation or testing, call us at (347) 970-8479 or schedule your initial consultation now.
Written by the New Hope Editorial Team
As experts in IVF and Assisted Reproductive Technologies, we are committed to educating and empowering people on their fertility journey with accurate information and compassionate care.